Metformin

Metformin is FDA-approved only for type 2 diabetes and diabetes prevention in high-risk prediabetics (DPP protocol). Off-label use in non-diabetic adults for longevity, cardiovascular prevention, or weight management is not FDA-approved but is increasingly common among some physicians and longevity clinics. The strongest non-diabetic evidence base is for PCOS and prediabetes. For healthy non-diabetic adults, the evidence supporting metformin for longevity is preclinical and observational — not yet established through randomized controlled trials. The TAME trial (Targeting Aging with Metformin) is designed to fill this evidence gap but has not yet reported. BodyHackGuide's position is that off-label longevity metformin is a reasonable individual choice for informed adults who understand the uncertainty and monitor appropriately, but is not evidence-based enough to strongly recommend.

The human evidence for metformin lifespan extension is observational and suggestive but not yet definitive. The Bannister et al. 2014 (PMID 25041462) study showed that metformin-treated T2DM patients outlived matched non-diabetic controls, which was hypothesis-generating for the geroscience community. However, this observational comparison has important confounders (baseline BMI differences, healthcare utilization patterns, other unmeasured factors). Preclinical data in mice (Martin-Montalvo 2013, PMID 23900178) and worms shows modest lifespan extension (typically 5-10% in mice) — real but not dramatic. The TAME clinical trial will provide the first randomized controlled data but has not yet reported results. For now, the human longevity claim is supported by strong mechanistic rationale and modest observational and preclinical evidence, but is not proven. See /compound/rapamycin and /compound/nmn for related longevity-oriented compounds with similar evidence-base gaps.

Yes, this appears to be a real effect. Konopka et al. 2019 (PMID 31557590) randomized healthy older adults to 12 weeks of aerobic training plus metformin or placebo and found 60% smaller improvements in VO2max with metformin. Walton et al. 2019 MASTERS trial (PMID 31402259) similarly showed metformin attenuated muscle hypertrophy gains from resistance training in older adults. The mechanism likely involves metformin's complex I inhibition interfering with the mitochondrial biogenesis and oxidative phosphorylation adaptations that exercise normally produces, and AMPK-mTORC1 interactions that reduce training-induced protein synthesis. For athletes or individuals prioritizing exercise-based fitness gains, this represents a real tradeoff and an argument against metformin for non-diabetic longevity purposes. Some practitioners suggest timing metformin doses away from training sessions or cycling off metformin during intensive training periods, but these strategies are uncontrolled. For T2DM patients, the glycemic and cardiovascular benefits of metformin typically outweigh the exercise-attenuation effect.

Chronic metformin use reduces vitamin B12 absorption through multiple mechanisms including interference with intrinsic factor-B12 complex binding to ileal receptors. Aroda et al. 2016 (PMID 26908272) in the DPP Outcomes Study documented 4-5% absolute increase in B12 deficiency over 5 years of metformin use. Clinical consequences range from subclinical lab abnormalities to overt megaloblastic anemia, peripheral neuropathy, and cognitive symptoms in severe cases. Recommendations: baseline B12 measurement before metformin initiation, periodic monitoring (every 1-2 years) during chronic use, and prophylactic oral cobalamin supplementation (500-1,000 mcg daily) is reasonable for most chronic users. Risk increases with duration, dose, and older age. Symptoms suggesting B12 deficiency (fatigue, paresthesias, cognitive symptoms, macrocytosis on CBC) warrant prompt testing and replacement.

Immediate-release metformin (generic, Glucophage) is the older tablet formulation dosed 2-3 times daily with meals. Extended-release formulations (Glucophage XR, Glumetza, Fortamet) use sustained-release matrix technology to release drug slowly, allowing once-daily dosing. Glycemic efficacy is equivalent at matched total daily doses. The practical differences are: (1) GI tolerability — XR produces less diarrhea and nausea, particularly important for initiating therapy and long-term adherence; (2) dosing convenience — once daily XR versus 2-3× daily IR is easier for most users; (3) cost — XR is generally 3-5× more expensive than generic IR, though still very affordable; (4) flexibility — IR allows finer dose titration and split-dose optimization. For most patients, XR is preferred for chronic use; IR is acceptable for patients who tolerate it or where cost is limiting.

Lactic acidosis is the historically feared adverse event of biguanide therapy (responsible for withdrawal of phenformin in the 1970s), but for metformin specifically the modern incidence is low at approximately 3-10 per 100,000 patient-years in well-monitored populations. Clinically significant events almost always involve additional precipitating factors: acute renal failure, severe dehydration, sepsis, severe heart failure with hypoperfusion, alcohol intoxication, or iodinated contrast administration in renal impairment. Prevention is the main strategy: avoid metformin in eGFR <30, reduce dose in eGFR 30-45, temporarily hold around major surgery or contrast, and discontinue during severe acute illness or hemodynamic instability. For appropriately-selected and monitored patients, metformin-associated lactic acidosis is a rare complication and should not deter use when indicated.

The TAME (Targeting Aging with Metformin) trial was proposed by Nir Barzilai and colleagues in 2016 (PMID 27304512) as a 6-year multicenter placebo-controlled RCT in 3,000 non-diabetic adults aged 65-79 with age-related disease as a composite primary endpoint. The trial has faced persistent funding challenges because the FDA does not currently recognize aging as an indication, making industry sponsorship difficult, and because trial cost estimates ($35-40 million) are substantial. Through 2025-2026, the trial has progressed under various academic and private funding arrangements; for the latest status, check the American Federation for Aging Research (AFAR) or Einstein Institute for Aging Research updates. The trial's importance to geroscience is substantial — regardless of outcome, it will be the first large-scale RCT test of a candidate geroprotective drug in healthy older adults and will inform regulatory frameworks for future aging-indication drug approval.

Metformin produces modest weight loss (typically 1-3 kg) in T2DM and prediabetic populations, less in healthy-weight non-diabetic individuals. This is substantially less than GLP-1 receptor agonists (5-20% body weight loss with semaglutide and tirzepatide — see /compound/semaglutide, /compound/tirzepatide) or surgical approaches. The weight effect is mediated primarily through GDF15 signaling (appetite reduction) and gut-microbiome-mediated metabolic effects. For individuals with obesity and metabolic syndrome, metformin is a reasonable first-line addition to dietary and exercise intervention. For obesity in isolation without metabolic syndrome, GLP-1 agonists or surgical approaches have superior weight-loss magnitude. Metformin is not a weight-loss drug per se but can be one component of comprehensive metabolic management.

Combinations of metformin with rapamycin (/compound/rapamycin) or NAD+ precursors (/compound/nmn, /compound/nad) are popular in longevity-oriented protocols and have plausible mechanistic rationale — metformin activates AMPK, rapamycin inhibits mTORC1 (convergent on autophagy and anti-aging pathways), and NAD+ precursors support sirtuin-mediated metabolic regulation. However, these combinations have not been tested in controlled human trials for longevity outcomes. Each agent has its own risk profile (metformin: GI effects, B12 deficiency; rapamycin: immunosuppression, lipid changes, wound healing; NAD+ precursors: generally well-tolerated but unclear long-term effects). Combining them multiplies uncertainty about both individual and combined safety-efficacy balance. For informed individuals accepting this uncertainty, the combinations are rational; the recommendation to pursue them for longevity requires honest acknowledgment that they are investigational rather than evidence-based.

Glycemic effects: metformin begins reducing hepatic glucose output within days of starting therapy, with measurable HbA1c reduction typically seen by 4-8 weeks and reaching near-maximum effect by 12 weeks. Fasting glucose often improves within 2-4 weeks. Weight effects: modest weight loss typically develops over 3-6 months. PCOS menstrual regularity: improvements over 3-6 months in most responders. Prediabetes progression: the DPP 31% reduction in diabetes incidence develops over 2-3 years of continuous therapy. Cardiovascular outcome benefits (UKPDS): develop over years of treatment in T2DM. For off-label longevity use: the theoretical benefits (if real) would develop over years-to-decades, making meaningful individual-level feedback about benefit challenging. Some practitioners use biological age markers (epigenetic clocks, inflammatory markers) as interim proxies, though the evidence supporting this is limited. For clinical indications, non-response at expected timeframe warrants evaluation for adherence, dose adequacy, and differential diagnosis.